Project Grant R44AI191886
Award Date
5/16/25
Completion Date
4/30/28
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on the discovery and development of novel schistosomicidal (anti-schistosome) agents. The $600,000 award, with a period of performance from June 2024 to May 2025, will support research to optimize novel inhibitors of the schistosome enzyme thioredoxin glutathione reductase (TGR) for oral bioavailability, while...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $243,361 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Rush University Medical Center in Chicago, Illinois. The grant will support a project to establish workflows for rapid and inexpensive whole genome sequencing (WGS) of Neisseria gonorrhoeae (NG) directly from urine, throat, and rectal clinical specimens. The goal is to enhance surveillance for emerging strains of NG with reduced...
The federal Project Grant award R21AI188783, totaling $229,411, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at Northwestern University to investigate the production of double-stranded bacteriophages in the human pathogen Neisseria gonorrhoeae. The key goals are to determine if one or more phage islands can produce phage particles, explore the regulation of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,999 to Planet Biotechnology Incorporated to develop a novel bispecific antibody for the prevention of gonorrhea. The company will engineer a fusion protein that combines elements of a human antibody (2C7) with a human immune system component (Factor H) to enhance the complement-mediated killing of the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $787,171 to develop a new class of anti-tuberculosis (TB) compounds. The award supports research to discover and optimize 1,2,4-triazole and pyrrolidine compounds that inhibit the growth of drug-resistant strains of Mycobacterium tuberculosis, the causative agent of TB. The research aims to understand the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Topaz Biosciences, Inc., a woman-owned small business located in Emeryville, California. The funding will support the company's research to discover and optimize novel endolysins that can selectively target Gardnerella vaginalis, a key bacterial species associated with bacterial vaginosis (BV). The project aims to expand...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,530 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Scientific Horizons Consulting LLC. The grant supports the development of a novel antibiotic delivery system using cyclodextrin-based metal-organic frameworks (CD-MOFs) to treat non-tuberculous mycobacterial (NTM) lung infections. Key innovations include high antibiotic loading ratios, improved bioavailability and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop rapid, point-of-care testing capabilities for detecting antibiotic resistance in Treponema pallidum, the causative agent of syphilis. Specifically, the project aims to develop two complementary approaches: 1) an allele-specific loop-mediated isothermal amplification (AS-LAMP) assay for a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to President and Fellows of Harvard College to conduct research focused on developing novel antibiotics to address the challenge of multi-drug resistant bacterial pathogens. The research aims to synthesize and evaluate new antibiotic compounds that target the lipoprotein transport pathway in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $233,250.00 to the University of Washington to investigate nitroimidazole susceptibility and mechanisms of resistance in Mycoplasma genitalium. M. genitalium is a sexually transmitted bacterial pathogen that frequently causes genital tract infections, but treatment options are limited due to increasing antibiotic...